We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Rua Life Sciences Plc | RUA | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 10.75 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 10.75 | 10.75 | 10.75 | 10.75 | 10.75 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 27/3/2024 13:44 by cocker Bones, you seem like a well educated well read guy, but exactly when will you concede defeat here. Elaston for example is supposed to be world beating coating that has barely gained any traction over many years & that's only part of the business that basically is failing. The carrot has been dangled on many occasions only to find that the only thing that investors can be sure of , is the regular begging bowl to fund Williams lavish lifestyle. |
Posted at 07/3/2024 14:32 by bones Don’t see why they wouldn’t update in May/June, assuming nothing specific to report before then (eg, licensing news or new MTA). There should be stuff to update for the new investors especially. We all want to know how the divisions are doing and there should have been material reductions in costs following the reduction in R&D on the graft. Plenty to say imo. |
Posted at 02/1/2024 14:26 by edmonda Investor Presentation video recording (Interim Results) - 19th December 2023Bill Brown (Chairman) and Lachlan Smith (Chief Financial Officer) of RUA Life Sciences hosted an online presentation for investors. The team covered highlights of their Interim Results (to 30th September) and the successful fund raise announced after period end. Management discussed the shorter-term commercialisation opportunities present in RUA Structural Heart and RUA Contract Manufacture, and how the agreed regulatory pathway enables engagement with potential partners to facilitate the commercialisation of RUA Vascular. The team also answered a range of questions from viewers. The full video is available below, divided into chapters: 0:00:11 Introduction to RUA Life Sciences 0:01:13 Financial overview (Interim Results) 0:06:01 Segmental analysis 0:07:03 Portfolio Businesses 0:08:34 What is Elast-Eon™? 0:11:17 Contract Manufacturing 0:14:25 Structural Heart 0:24:32 Vascular 0:29:06 Portfolio Management & Summary (including completed fund raise) 0:32:32 Questions & Answers Link to watch presentation: |
Posted at 19/12/2023 14:59 by bones Webinar thoughts:I’m always amazed Zoom stays relevant as a business. As is true on many webinars (not just RUA), the broadcast quality sounds like Neil Armstrong’s from the moon in 1969. Most investors seem to have lost interest. Apart from the first, the remaining questions were mine and were somewhat fishing for specifics. Not surprising most were knocked back as any talks going on with industry are not going to be for publication anyway until deals are done, if any. The preamble was a repeat of some of the fund raising presentation summarising the businesses. Ultimately it remains a play on what the new investors have been led to believe in persuading them to invest at this low price. A patient game. Pretend you are an EIS investor with three years minimum to hold. Don’t expect fireworks next month! That way any announcements of note will be a pleasant occurrence… |
Posted at 12/12/2023 14:52 by slicethepie You really think the shorters are not professional investors? Private investors don't have access to such tactics unless using sites like Ig index .....hope they get a real kicking ! |
Posted at 04/12/2023 13:20 by hedgehog11 Thanks for both those comments, I find these dialogues really useful.As you have both stated, even in the most recent updates RUA have further damaged credibility and trust and that has got to be a massive turn off for investors. I'm wondering if the recent placing will limit future misdirection and general game playing from RUA - by that I mean that the company will be just shy of two thirds owned by institutional investor (up from 25%). I am making an assumption here but does that massively increase the pressure on the board to play nicely, or is that not a concern to directors? I am assuming we won't know which institutions have what level of interest in the business until after the next GM later this month when they vote on all this? |
Posted at 01/12/2023 13:09 by donalc This is the cold reality.They dont really care about us the small retailer investor. They will have lost quiet a few of us. They will have gained some new institutional investors at new bargain price. I am guessing the board was divided on this. But probably there advisor came in with a we have a short window of oppurtunity and lined up a few investors. Feel really sorry for all the long term investors here who bought in years ago (including me!). Loyality in financial world does not pay. Authentic leaders do not exist. All about the £ sign. Glad I live in a very different world. |
Posted at 24/11/2023 11:01 by drradcliffe What's interesting is Equity Development weren't expecting a trading update. They seemed to think the 20/11/23 Strategy Update replaced a trading update.From their note 21/11/23: "Strategy Update In place of the trading statement which is usually released at this time of year, and ahead of RUA Life Sciences’ interim results, RUA has released a more material - and very well-received - strategy update." "Sticking to its objectives In place of a trading statement that updates investors on the progress of its revenue-generating businesses and its products in development, RUA’s strategy update has been well-received by investors because it outlines the path of the business to greater and earlier revenues than we had expected in RUA Contract Manufacture and RUA Structural Heart. The strategy also lowers the risks for investors compared to funding the development of RUA’s products solely by an equity offering, at a time where life science markets are depressed and the potential dilution punitive." Does this mean the market itself wasn't expecting this trading update? I wonder whether it was a very recent decision to do this in order to stabilise the share price, and specifically on a Friday morning to get rid of the short term traders? If you are going to arrange a small placing, the last thing you want is a highly volatile share price. |
Posted at 21/11/2023 10:19 by edmonda Strategy Update, sticking to its objectives - new note from Equity Development (link here: In place of the trading statement which is usually released at this time of year, and ahead of RUA Life Sciences’ interim results, RUA has released a more material - and very well-received - strategy update. In place of a trading statement that updates investors on the progress of its revenue-generating businesses and its products in development, RUA’s strategy update has been well-received by investors because it outlines the path of the business to greater and earlier revenues than we had expected in RUA Contract Manufacture and RUA Structural Heart. The strategy also lowers the risks for investors compared to funding the development of RUA’s products solely by an equity offering, at a time where life science markets are depressed and the potential dilution punitive. RUA Contract Manufacture, the contract manufacturer of medical devices using implantable fabrics with a biocompatible Elast-Eon coating, is responding to a formal bid request that could result in around £2m in revenues, with much of that recuring on an annual basis. Thus, RUA’s board’s objective of doubling the scale of the contract manufacturing business in the medium term is on track. |
Posted at 27/7/2023 22:08 by slicethepie The share register says it all, the only proper investor is dowgate. Bb has failed to attract new investors and clearly scared off their only other investor Amati. This needs a new chairman who investors have confidence in. Bb has been here over 12 years way, this business deserves better imo |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
